Expectations trend
FY2027 · fiscal year ending 2027-12-31 · fmp
KAILERA THERAPEUTICS INC (KLRA)
NASDAQHealth CareBiotechnologySnapshot 2026-11-05
$12.17-4.92%
Close 2026-11-05 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-05
The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.
Next-FY EPS estimate change · 30 days
Matching fiscal periods, usable estimates and at least one analyst are required.
One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.
The calculation requires same-period, same-provider snapshots, positive EPS, at least one analyst and a baseline within three days of the requested lookback.
The EPS and P/E reference is not available for KLRA yet.
| Measure / period | Management expectations | Analyst expectations |
|---|
Management figures unavailable.
Current consensus figures unavailable.
4 published thesis conditions, with dated milestones shown separately.
| Key Factor | Why It Matters | Current Status | Break Condition | Latest Evidence |
|---|---|---|---|---|
advance clinical trial milestones for obesity drug Ribupatide | Kailera is advancing gene therapies for rare diseases with strong clinical progress. | Improving | failure to report positive Phase 3 data or significant trial delays in FY26 | Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Date unavailableLast status assessment Nov 5, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Compare these dated observations with the operating requirements above
FY2027 · fiscal year ending 2027-12-31 · fmp
The evidence, the remaining questions, and what comes next
No recovery evidence is reported in the available driver assessments.
Observed price history; separate from operating scenarios
The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.
This is a clinical-development growth story, with potential tied to obesity treatments still being tested. The long-term thesis is supported by progress on ribupatide trials, but the overall thesis state is insufficient because recent financial history is limited.
The evidence snapshot provides no valuation measures or clear account of market expectations, so whether KLRA is cheap or expensive versus peers is unclear. Recent share-price reaction is reported as down, but that alone does not show what expectations are already reflected.
Near term, earnings risk is elevated: KLRA missed in the two recorded recent quarters, and the snapshot flags a high chance of another miss. Over the multi-year view, management is on track with ribupatide enrollment and development, while the oral KAI-7535 program is progressing with mixed status and 2027 data expected.
The multi-year thesis hinges on trial results, including ribupatide oral Phase 3 plans for the first half of 2027, KAI-7535 data expected in 2027, and ribupatide injection data anticipated in 2028. Near-term conditions also matter: weakening jobs data could weigh on cyclical names, while healthcare-sector momentum depends in part on whether bellwethers continue to report strong results and guidance.
KLRA has clear clinical milestones ahead, but its financial record in this snapshot is too thin to support a firm read, and near-term earnings risk is elevated. The 1-to-3-year thesis remains uncertain and depends on trial progress and results. Not investment advice.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
| A primary condition in KAILERA THERAPEUTICS INC's published investment case. The stated target is sustain cash runway through at least end of 2027. |
| Intact |
| need for dilutive capital raise before end of 2027 |
Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Date unavailableLast status assessment Nov 5, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
strengthen corporate leadership and strategic execution | New leadership may improve corporate strategy. | Improving | no visible strategic progress or leadership instability in FY26 | Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Date unavailableLast status assessment Nov 5, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
reduce net losses and improve EPS trajectory | A primary condition in KAILERA THERAPEUTICS INC's published investment case. The stated target is EPS loss narrows from -4.29 in FY26 to less negative in FY27. | Intact | EPS loss worsens or remains flat beyond FY27 | Diluted EPS: $-0.74 per share FY2026-Q3; GAAP. Published target: EPS loss narrows from -4.29 in FY26 to less negative in FY27. Annual target cannot be compared with a quarterly or TTM observation. Nov 4, 2026-0.74 USD/share · source valueLast status assessment Nov 5, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.
$-3.84 → $-4.30 · observed estimates
Unavailable → Unavailable · observed estimates
One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.
| Snapshot | EPS | Revenue | EPS / revenue analysts |
|---|---|---|---|
| 2026-07-24 | $-3.84 | Unavailable | 4 / 0 |
| 2026-07-25 | $-3.84 | Unavailable | 4 / 0 |
| 2026-07-26 | $-3.84 | Unavailable | 4 / 0 |
| 2026-07-27 | $-3.84 | Unavailable | 4 / 0 |
| 2026-07-28 | $-3.84 | Unavailable | 4 / 0 |
| 2026-07-29 | $-3.84 | Unavailable | 4 / 0 |
| 2026-07-30 | $-3.84 | Unavailable | 4 / 0 |
| 2026-07-31 | $-3.84 | Unavailable | 4 / 0 |
| 2026-08-01 | $-3.84 | Unavailable | 4 / 0 |
| 2026-08-02 | $-3.84 | Unavailable | 4 / 0 |
| 2026-08-03 | $-3.84 | Unavailable | 4 / 0 |
| 2026-08-04 | $-3.84 | Unavailable | 4 / 0 |
| 2026-08-05 | $-3.84 | Unavailable | 4 / 0 |
| 2026-08-06 | $-3.84 | Unavailable | 4 / 0 |
| 2026-08-07 | $-3.84 | Unavailable | 4 / 0 |
| 2026-08-08 | $-3.84 | Unavailable | 4 / 0 |
| 2026-08-09 | $-3.84 | Unavailable | 4 / 0 |
| 2026-08-10 | $-3.84 | Unavailable | 4 / 0 |
| 2026-08-12 | $-4.10 | $0 | 3 / 6 |
| 2026-08-13 | $-3.84 | Unavailable | 4 / 0 |
| 2026-08-14 | $-3.84 | Unavailable | 4 / 0 |
| 2026-08-15 | $-3.84 | Unavailable | 4 / 0 |
| 2026-08-16 | $-3.84 | Unavailable | 4 / 0 |
| 2026-08-17 | $-3.84 | Unavailable | 4 / 0 |
| 2026-08-18 | $-3.84 | Unavailable | 4 / 0 |
| 2026-08-19 | $-3.84 | Unavailable | 4 / 0 |
| 2026-08-20 | $-4.62 | Unavailable | 4 / 0 |
| 2026-08-21 | $-4.62 | Unavailable | 4 / 0 |
| 2026-08-22 | $-4.62 | Unavailable | 4 / 0 |
| 2026-08-23 | $-4.62 | Unavailable | 4 / 0 |
| 2026-08-24 | $-4.62 | Unavailable | 4 / 0 |
| 2026-08-25 | $-4.62 | Unavailable | 4 / 0 |
| 2026-08-26 | $-4.62 | Unavailable | 4 / 0 |
| 2026-08-27 | $-4.62 | Unavailable | 4 / 0 |
| 2026-08-28 | $-4.62 | Unavailable | 4 / 0 |
| 2026-08-29 | $-4.62 | Unavailable | 4 / 0 |
| 2026-08-30 | $-4.62 | Unavailable | 4 / 0 |
| 2026-08-31 | $-4.62 | Unavailable | 4 / 0 |
| 2026-09-01 | $-4.62 | Unavailable | 4 / 0 |
| 2026-09-02 | $-4.62 | Unavailable | 4 / 0 |
| 2026-09-03 | $-4.62 | Unavailable | 4 / 0 |
| 2026-09-04 | $-4.62 | Unavailable | 4 / 0 |
| 2026-09-05 | $-4.62 | Unavailable | 4 / 0 |
| 2026-09-06 | $-4.62 | Unavailable | 4 / 0 |
| 2026-09-07 | $-4.62 | Unavailable | 4 / 0 |
| 2026-09-08 | $-4.62 | Unavailable | 4 / 0 |
| 2026-09-09 | $-4.62 | Unavailable | 4 / 0 |
| 2026-09-10 | $-4.62 | Unavailable | 4 / 0 |
| 2026-09-11 | $-4.62 | Unavailable | 4 / 0 |
| 2026-09-12 | $-4.62 | Unavailable | 4 / 0 |
| 2026-09-13 | $-4.62 | Unavailable | 4 / 0 |
| 2026-09-14 | $-4.62 | Unavailable | 4 / 0 |
| 2026-09-15 | $-4.62 | Unavailable | 4 / 0 |
| 2026-09-16 | $-4.62 | Unavailable | 4 / 0 |
| 2026-09-17 | $-4.62 | Unavailable | 4 / 0 |
| 2026-09-18 | $-4.62 | Unavailable | 4 / 0 |
| 2026-09-19 | $-4.62 | Unavailable | 4 / 0 |
| 2026-09-20 | $-4.62 | Unavailable | 4 / 0 |
| 2026-09-21 | $-4.62 | Unavailable | 4 / 0 |
| 2026-09-22 | $-4.62 | Unavailable | 4 / 0 |
| 2026-09-23 | $-4.62 | Unavailable | 4 / 0 |
| 2026-09-24 | $-4.62 | Unavailable | 4 / 0 |
| 2026-09-25 | $-4.62 | Unavailable | 4 / 0 |
| 2026-09-26 | $-4.62 | Unavailable | 4 / 0 |
| 2026-09-27 | $-4.62 | Unavailable | 4 / 0 |
| 2026-09-28 | $-4.62 | Unavailable | 4 / 0 |
| 2026-09-29 | $-4.62 | Unavailable | 4 / 0 |
| 2026-09-30 | $-4.62 | Unavailable | 4 / 0 |
| 2026-10-01 | $-4.62 | Unavailable | 4 / 0 |
| 2026-10-02 | $-4.62 | Unavailable | 4 / 0 |
| 2026-10-03 | $-4.30 | Unavailable | 4 / 0 |
| 2026-10-04 | $-4.30 | Unavailable | 4 / 0 |
| 2026-10-05 | $-4.30 | Unavailable | 4 / 0 |
| 2026-10-06 | $-4.30 | Unavailable | 4 / 0 |
| 2026-10-07 | $-4.30 | Unavailable | 4 / 0 |
| 2026-10-08 | $-4.30 | Unavailable | 4 / 0 |
| 2026-10-09 | $-4.30 | Unavailable | 4 / 0 |
| 2026-10-10 | $-4.30 | Unavailable | 4 / 0 |
| 2026-10-11 | $-4.30 | Unavailable | 4 / 0 |
| 2026-10-12 | $-4.30 | Unavailable | 4 / 0 |
| 2026-10-13 | $-4.30 | Unavailable | 4 / 0 |
| 2026-10-14 | $-4.30 | Unavailable | 4 / 0 |
| 2026-10-15 | $-4.30 | Unavailable | 4 / 0 |
| 2026-10-16 | $-4.30 | Unavailable | 4 / 0 |
| 2026-10-17 | $-4.30 | Unavailable | 4 / 0 |
| 2026-10-18 | $-4.30 | Unavailable | 4 / 0 |
| 2026-10-19 | $-4.30 | Unavailable | 4 / 0 |
| 2026-10-20 | $-4.30 | Unavailable | 4 / 0 |
| 2026-10-21 | $-4.30 | Unavailable | 4 / 0 |
| 2026-10-22 | $-4.30 | Unavailable | 4 / 0 |
| 2026-10-23 | $-4.30 | Unavailable | 4 / 0 |
| 2026-10-24 | $-4.30 | Unavailable | 4 / 0 |
| 2026-10-25 | $-4.30 | Unavailable | 4 / 0 |
| 2026-10-26 | $-4.30 | Unavailable | 4 / 0 |
| 2026-10-27 | $-4.30 | Unavailable | 4 / 0 |
| 2026-10-28 | $-4.30 | Unavailable | 4 / 0 |
| 2026-10-29 | $-4.30 | Unavailable | 4 / 0 |
| 2026-10-30 | $-4.30 | Unavailable | 4 / 0 |
| 2026-10-31 | $-4.30 | Unavailable | 4 / 0 |
| 2026-11-01 | $-4.30 | Unavailable | 4 / 0 |
| 2026-11-02 | $-4.30 | Unavailable | 4 / 0 |
| 2026-11-03 | $-4.30 | Unavailable | 4 / 0 |
| 2026-11-04 | $-4.30 | Unavailable | 4 / 0 |
| 2026-11-05 | $-4.30 | Unavailable | 4 / 0 |
Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.
Latest: 6 Buy / Strong Buy · 0 Hold · 0 Sell / Strong Sell
Recent actions · Oct 7–Nov 5 · 0 recorded
Individual price-target observations are unavailable.
0 raises · 0 cuts · 0 unchanged · 0 without a comparable prior
Oct 7, 2026–Nov 5, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.
Next earnings date unavailable
Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.
Review earnings4 of 4 published conditions remain under pressure or need verification. The next results need to address those conditions.
The dated weekly assessment and its assumptions are available in Read detailed Outlook.